Windhover Information Inc.:
-- Premier networking event to include AZ, Bayer, BMS, Wyeth, GSK and more
-- September 25-27, 2006 Marriott Financial Center, New York, NY
Space is filling fast for the blockbuster 2006 Pharmaceutical Strategic Alliances Conference, sponsored by Windhover Information.
PSA is the premier informational and networking event in the industry. It is scheduled for Sept. 25-27 at the Marriott Financial Center, New York, NY. Registrations are still being accepted at http://www.windhover.com/dotcom/conferences/index.asp?page=psa.
Among the companies already signed up to attend are Abbott Laboratories Inc., Allergan Inc., AstraZeneca, Bausch & Lomb Pharmaceuticals Inc., Bayer Corporation, Bristol-Myers Squibb Company, Edwards Angell Palmer & Dodge LLP, Eli Lilly & Co., Ernst & Young, FibroGen Inc., Fidelity Investments, GlaxoSmithKline Inc., Jazz Pharmaceuticals Inc., Johnson & Johnson, Lehman Brothers, Lilly Research Laboratories, Merck & Co. Inc., Novartis, Novo Nordisk AS, Pfizer Inc., PricewaterhouseCoopers, Rinat Neuroscience, Roche, Schering, Procter & Gamble Company, and Wyeth Pharmaceuticals.
PSA has a history as a prominent event, always attracting the top companies and important speakers, with past attendees calling it "well thought-out and ... very pertinent," "one of the 'most attended' conferences," and "a thoughtful combination of topics together with insightful commentary and questioning by moderators."
Special workshop, eminent speakers planned
PSA will feature a special workshop, moderated by Carl V. Sailer, Vice President, Marketing and Business Development, PDI Inc. and titled "Minimizing Commercialization Risk: Weighing Options in Creating an Effective Product Launch." The highly interactive workshop, sponsored by PDI, will feature case study reviews of two emerging/specialty pharma and two from large pharma. Teams develop their own solutions to each case, followed by a presentation that outlines what actually happened. This will be a no-holds-barred discussion that is likely to be controversial. Those interested, whether attending PSA or not, may register for the workshop at http://188.8.131.52/content/onl_registration2.asp?skuarr=2006011007.
PSA is focused this year on models of externalization, and is designed to help healthcare industry executives maximize their strategic alliance opportunities by hearing CEOs, Senior R&D and Senior Business Development executives share lessons learned, practical advice and strategies on how to build the R&D pipeline, both internally and externally. To accomplish this, Windhover has lined up a number of top executives to address the conference on a wide variety of stimulating topics.
-- Dr. Steven Marc Paul, Executive Vice President of Science and Technology and President of the Lilly Research Laboratories (LRL) at Eli Lilly, will speak on "What Lilly Looks for ... Outside" at the conference. Other speakers at PSA 2006 will include:
-- Elliott Sigal, MD, PhD, Chief Scientific Officer, Bristol-Myers Squibb Co. and President, Bristol-Myers Squibb Pharmaceutical Research Institute - "Building and Externalizing BMS"
-- Roch Doliveux, CEO, UCB - "Transforming UCB by Acquisition -- Part 1"
-- Randall Scott, CEO, Genomic Health - "The Rx/Dx Divide...and the Need to Bridge It"
-- Roger Longman, Managing Partner, Windhover Information - "Dealmaking Year in Review...and What to Expect in 2007"
-- Edmund Harrigan, Worldwide Head of Regulatory Affairs, Pfizer; and Peter Honig, EVP, WW Reg. Affairs, Merck - "Issues in Regulation: Cooperation & Competition"
-- Cavan Redmond, Vice President and General Manager, BioPharma Business Unit, Wyeth Pharmaceuticals - "In-Licensing Large Molecules"
-- Peter Hug, Head of Pharma Partnering, Roche - "Dealmaking at the Industry's Most Externalized Company"
-- Ted W. Love, MD, Chairman and CEO, Nuvelo - "Bayer/Nuvelo: Classic Regional Deal, Not-So-Classic Partner"
-- Victor Hartmann, MD, EVP Strategic & Corporate Development, Vertex - "Vertex/J&J: New Regional Deal Dynamics"
-- Alex Scott, VP, Business Development, Eisai Inc. - "A Regional Player Comes to the US"
-- John McLaughlin, CEO, Anesiva - "Private to public from the public POV"
-- Jeffrey Tong, Ph.D., VP of Corporate and Product Development, Infinity & Discovery Partners - "Private to public from the private POV"
-- Rusty Johnson, Managing Director, WR Hambrecht - "Taking the bypass via auction"
-- George Vergis, CEO, Neose - "The Challenge of Differentiating 2nd Generation Biologicals"
-- Nayan Gregory Parekh, PhD, Head of Corporate Mergers & Acquisitions, Novartis AG - "Buying & Building Businesses Outside Traditional Pharma"
-- Stephen Sands, Managing Director, Lazard - "The 3rd Annual M&A Trends Survey"
-- Ron Eastman, CEO, Rinat; Lisa Ricciardi, SVP, Business Development & Licensing, Pfizer - "The Pfizer/Rinat Transaction ... from Both Sides of the Table"
PSA's global sponsors are McKinsey & Co.; Edwards, Angell, Palmer & Dodge LLP; Lazard; and Price Waterhouse Coopers. Industry sponsors are Astra Zeneca; Bristol-Myers Squibb; Merck; Eisai and Pfizer. Workshop sponsors are PDI Inc and IMS, and media sponsors are Business Wire and CanBiotech.
To register for the conference and/or the special workshop, contact Alexandria Riley at (203) 838-4401 ext. 113 or email@example.com; or register on the PSA 2006 Summit website at www.windhover.com/psa.
About Windhover Information
Windhover Information Inc. has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and audio conferences. For more on the company's products and services, please see www.windhover.com.